Ioanna Gouni-Berthold
Ioanna Gouni-Berthold, MD is an expert in Cardiology at University Hospital Cologne (Germany). As of September 2026, ScienceLeadR ranks Ioanna Gouni-Berthold in the top 1% of experts worldwide for Hyperlipidemias, Dyslipidemias and Lipid Metabolism Disorders. Ioanna Gouni-Berthold has authored 219 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 1 of them ongoing. SLR score: 775 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Endocrinology - Biochemistry - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 219
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| [Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study]. PMID 42345056 — cholesterol, ldl, pharmaceutical preparations, cardiovascular diseases, drug-related side effects and adverse reactions, cholesterol, therapeutics, hypercholesterolemia | G Ital Cardiol (Rome) | 2026 | 0 |
| Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial. PMID 42251764 — diabetes mellitus, cholesterol, ldl, stroke, absenteeism, atherosclerosis, hydroxymethylglutaryl-coa reductase inhibitors | Diabetes Care | 2026 | 0 |
| Safety of low lipoprotein(a) levels: the FOURIER trial. PMID 42234492 — diabetes mellitus, safety, lipoproteins, cardiology, therapeutics, lipoprotein(a) | Eur Heart J Top journal | 2026 | 0 |
| From static lipids to dynamic risk: The role of atherogenic index of plasma in prediabetes. PMID 42185132 — diabetes mellitus, prediabetic state, plasma | J Diabetes Complications | 2026 | 0 |
| Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial. PMID 42153665 — stroke, cardiovascular system, percutaneous coronary intervention, blood circulation | Circulation Top journal | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230) 2024-519870-38-00 — safety, cardiovascular diseases | Phase 3 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map